{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"89"}]}],"title":"TEAE-Any Grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"86"}]}],"title":"TEAE-Grade 3/4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}],"title":"TEAE-Grade 5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"70"}]}],"title":"TEAE Related to LN-144- Any Grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"32"}]}],"title":"TEAE Related to LN-144-Grade 3/4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"TEAE Related to LN-144-Grade 5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"TEAE leading to LN-144 discontinuation -Any Grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"TEAE leading to LN-144 discontinuation- Grade 3/4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"TEAE leading to LN-144 discontinuation-Grade 5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"31"}]}],"title":"Treatment-Emergent SAE- Any Grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"29"}]}],"title":"Treatment-Emergent SAE- Grade 3/4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}],"title":"Treatment-Emergent SAE- Grade 5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}],"title":"Treatment-Emergent SAE related to LN-144-Any Grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}],"title":"Treatment-Emergent SAE related to LN-144-Grade 3/4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Treatment-Emergent SAE related to LN-144-Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"89"}],"units":"Participants"}],"description":"Incidence, seriousness, relationship to study treatment, and characteristics of treatment-emergent adverse events","groups":[{"description":"Non-cryopreserved LN-144 (Gen 1 infusion product) (Closed)","id":"OG000","title":"Cohort 1"},{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)","id":"OG001","title":"Cohort 2"},{"description":"Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b) (Closed)","id":"OG002","title":"Cohort 3"},{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)","id":"OG003","title":"Cohort 4"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Analysis Set is defined as patients who received the LN-144 infusion. Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen.","reportingStatus":"POSTED","timeFrame":"Maximum 60 months","title":"Safety Profile","type":"SECONDARY","unitOfMeasure":"Participants"}